Clinical Observation Of Imatinib In Treatment Of Patients With Chronic Myeloid Leukemia In Chronic Phase And Dvanced Phase

Purpose:To observe the effects of imatinib mesylate (IM) for treatment of Philadelphia chromosome positive (Ph) and (or) BCR/ABL Fusion gene positive chronic myelogenous leukemia (CML) in the clinical curative effect of chronic and advanced and conventional therapy.Methods:Retrospective analysis of November November since20052012in the chronic phase, a total of/09cases in our hospital treatment of34cases of advanced CML patients (Ph chromosome and BCR/ABL fusion gene was positive) were retrospectively analyzed, according to the treatment of patients with blood cell count, bone marrow cell genetics and molecular biological changes to the curative effect evaluation.Results:1. CML:epidemiological characteristics of male:female incidence ratio for1.71:1, the median age was51years, the peak age of onset between the ages of45-55.2. chronic phase CML to imatinib treatment group (treatment group43cases) and control group (44cases). The treatment group in the3mCHR,6mPCyR,12mCCyR,18mCMR were higher than those of the control group, the difference was statistically significant (P<0.001).5years OS imatinib treatment group than the control group, with statistical difference (P=0.022).3.the progression of CML to imatinib treatment group (treatment group13cases) and control group (21cases), were treated with imatinib mesylate and combined chemotherapy treatment, the2groups were observed and compared with results of hematological changes the efficiency and adverse reaction of tolerance and other indicators of blood:treatment group total learning efficiency is44.4%, control group blood efficiency is7.1%,, there was statistically significant difference between2groups (P<0.01). Treating the adverse reaction of patients the drug is mainly sodium and water retention, but the total adverse reaction incidence rate and degree compared with the control group, mild, and easily tolerated.Conclusion:1.the CML statistics, the median age was51years old, the peak age of onset between the ages of45-55, show some aging.2. hydroxyurea, HHT on survival in patients with CML (median survival period of about4years) without significantly increased, interferon on survival in patients with CML than hydroxyurea extend the average about1years.3.The traditional therapy,3chronic phase CML imatinib treatment group long-term efficacy and5year OS is better than that of hydroxyurea, interferon, and well tolerated. And the treatment with imatinib advocated as early as possible.4. patients with CML in chronic phase CCR was obtained with the extension of treatment time and improve the.5. treatment with imatinib in chronic phase CML patients, adult daily400mg best, light adverse reactions. Can prolong progression free survival.6. the use of IM therapy in CML patients is a regular monitoring, can be found as soon as possible failure in the treatment of patients, timely change the treatment program, in order to improve the curative effect. 7. advanced CML and imatinib treated group were combined with chemotherapy group was significantly better than that of. And can make some patients progress to chronic period from. But the progress of remission rate was lower in chronic phase.8. the main adverse reaction of imatinib is sodium and water retention, and related to drug doses.